Table 2.

Antibody and T-cellular response to SARS-CoV-2 vaccination in patients 1 to 6.

Patient #	Analysis of antibody and T-cell response to SARS-CoV-2 after second vaccination	S protein- specific antibody response	T-cell response to antigen pools S1/S2 (IU/mL)	Analysis of antibody and T-cell response to SARS-CoV-2 after third vaccination	S protein- specific antibody response	T-cell response to antigen pools S1/S2 (IU/mL)
1	27 Jul 2021	<3.8 AU/mL	0	7 Sep 2021	4.31 AU/mL	0.0065
			0			0
2	9 Aug 2021	<3.8 AU/mL	0	19 Oct 2021	25.8 BAU/mL	0
			0			0.003
3	13 Sep 2021	<3.8 AU/mL	0	13 Dec 2021	7.65 BAU/mL	0
			0			0
4	5 Oct 2021	<4.81 BAU/mL	0	14 Dec 2021	<4.81 BAU/mL	0.0045
			0.0205			0.014
5	12 Oct 2021	<4.81 BAU/mL	0.0595	5 Jan 2022	7.43 BAU/mL	0
			0			0
6	13 Jul 2021	4.62 AU/mL	0	1 Nov 2021	12.5 BAU/mL	0
			0			0

AU/mL, Antibody Units per milliliter; BAU/mL, Binding Antibody Units per milliliter; IU/mL, International Units per milliliter. SARS-CoV-2-specific antibody and T-cell responses were measured after the second and again after the third vaccination of each patient. IgG antibodies against the spike protein of SARS-CoV-2 were measured via LIAISON^® SARS-CoV-2 S1/S2 IgG quantitative chemiluminescence immunoassay (DiaSorin; values < 12.0 AU/mL considered negative). From October 2021 onwards, antibodies were measured via LIAISON^® SARS-CoV-2 TrimericS IgG quantitative chemiluminescence immunoassay (DiaSorin; values < 33.8 BAU/mL considered negative). T-cellular interferon-gamma secretion to SARS-CoV-2 spike protein peptide pools 1 and 2 was measured via QuantiFERON^® SARS-CoV-2 assay (Qiagen; values < 0.15 IU/mL considered negative). All patients had negative antibody and T-cellular responses to SARS-CoV-2 spike protein after the second and third vaccination.